6-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

Form6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of December 2025

CommissionFile Number: 001-40678

EUDAHealth Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

OtherEvents.

On December 29, 2025, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Exhibit99.1

EUDA Health to Launch EUDA Helixé 2.0 in January 2026

SINGAPORE,Dec. 29, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it will launch EUDA Helixé 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging design, and global market readiness.

StrengthenedFormula and Ingredient Optimization

EUDA Helixé 2.0 features a 20% increase in New Zealand sourced deer placenta powder, with dosage enhanced from 100 mg to 120 mg, reinforcing the supplement’s positioning as a high potency vitality formulation. As part of the formulation upgrade, L-glutathione has been replaced with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent). This change is designed to improve antioxidant stability, support cellular protection, enhance skin health and bolster overall youthful vitality, aligning EUDA Helixé 2.0 with long-term wellness and anti-aging objectives.

AdvancedEncapsulation and Preservation Technology

EUDA Helixé 2.0 utilizes an upgraded ingredient preservation and delivery platform designed to enhance stability, absorption efficiency, and shelf life:

This nano-based delivery system enables EUDA Helixé 2.0 to achieve smaller capsule size and is designed to improve the user experience with efficient nutrient absorption while maintaining or enhancing functional efficacy.

NewProprietary Bottle Design

In conjunction with the product upgrade, EUDA is introducing a new proprietary EUDA Helixé bottle design, reflecting the supplement’s premium positioning while enhancing product protection, shelf presence and brand identity.

NewZealand Halal Certification and Global Market Expansion

EUDA Helixé 2.0 has obtained New Zealand Halal certification, enabling broader international distribution and formal entry into Muslim markets across Southeast Asia, the Middle East and other global regions.

PositioningEUDA Helixé for Global Growth

The upcoming January 2026 launch of EUDA Helixé 2.0 reflects EUDA Health’s commitment to continuous innovation, scientific advancement, and scalable global wellness solutions. With enhanced formulation strength, advanced delivery technology, refined packaging and expanded market accessibility, EUDA Helixé 2.0 is positioned as a core offering within EUDA’s growing health and longevity ecosystem.

MrAlfred Lim, CEO of EUDA, commented:

“This marks an important milestone in EUDA’s product evolution. With EUDA Helixé 2.0, we are strengthening our core formulation, upgrading delivery technology and expanding global market accessibility through Halal certification. These enhancements reflect our commitment to science-backed innovation and position EUDA Helixé as a premium longevity supplement aligned with EUDA’s broader strategy to scale high-quality wellness solutions globally.”

AboutEUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-LookingStatements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.